2 tracked superinvestors hold Newamsterdam Pharma Company (NAMS), worth $247M combined, led by Andreas Halvorsen. Smart money is holding NAMS as of the latest 13F filings.
Current price
$25.40
-1.0%
1Y
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular…
Market cap
$3.3B
P/E
-16.53
Div yield
0.0%
Revenue YoY
-50.6%
Analyst target
$51
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
2
tracked 13F / N-PORT funds
Combined value
$247M
disclosed long exposure
Tier-1 conviction
2
concentrated holders
Net this quarter
0
0 buying · 0 selling
Smart money is holding NAMS steady this quarter — buys and sells are balanced.
Newamsterdam Pharma Company (NAMS) is held by 2 tracked funds worth $247M combined, 2 of them concentrated Tier-1 managers whose positions carry real conviction.
The largest position belongs to Andreas Halvorsen at 0.4% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
Tracked holders were largely static this quarter — no new opens, adds or trims of size — suggesting the position is being held rather than actively traded.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Held | 0.4% | $142M | |
| Held | 2% | $104M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
Which superinvestors own NAMS?
2 tracked funds hold Newamsterdam Pharma Company (NAMS), the largest being Andreas Halvorsen (Viking Global Investors) at 0.4% of its 13F portfolio. 2 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling NAMS?
In the most recent 13F quarter, 0 tracked funds added or opened NAMS and 0 trimmed it.
How much NAMS do tracked funds hold?
Combined disclosed long exposure to NAMS across tracked superinvestors is $247M as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.